<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Pharmaceutical strategy for Europe (continuation of debate) - Thursday, 26 November 2020</title><meta name="title" content="Verbatim report of proceedings - Pharmaceutical strategy for Europe (continuation of debate) - Thursday, 26 November 2020" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2020 - Source: European Parliament" /><meta name="available" content="26-11-2020" /><meta name="sipade-leg" content="9" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Pharmaceutical strategy for Europe (continuation of debate) - Thursday, 26 November 2020" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-9-2020-11-26-ITM-006_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-9-2020-11-26-ITM-006_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2020-11-26-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2020-11-26-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2020-11-26-ITM-005_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2020-11-26-ITM-005_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-9-2020-11-26-ITM-007_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-9-2020-11-26-ITM-007_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-9-2020-11-26_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-9-2020-11-26_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)">
<table border="0" cellspacing="0" cellpadding="0"><tr>
<td><a href="/doceo/document/CRE-9-2020-11-26-ITM-006_EN.xml"><img src="/doceo/data/img/formats/icn_xml.gif" border="0" align="bottom" alt="XML" title="XML" /></a><span class="doc_size"> 43k</span></td></tr>
</table></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 26 November 2020 - Brussels</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 6. Pharmaceutical strategy for Europe (continuation of debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:46:35&amp;playerEndTime=20201126-10:17:40" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:46:35&amp;playerEndTime=20201126-10:17:40" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:46:35&amp;playerEndTime=20201126-10:17:40" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-9-2020-11-26-ITM-006_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-9-2020-11-26-ITM-006_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-9-2020-11-26-ITM-006_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="4-041-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4246.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:46:35&amp;playerEndTime=20201126-09:46:40" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Der Präsident. – </span></span>  Wir setzen nun unsere Aussprache über die Erklärung der Kommission zur Arzneimittelstrategie der EU (<a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2020/2878(RSP)">2020/2878(RSP)</a>) fort.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-042-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:46:40&amp;playerEndTime=20201126-09:47:47" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL).</span></span>   – Senhor Presidente, qualquer estratégia farmacêutica deve atender a dois requisitos fundamentais. </p>
<p class="contents">O primeiro requisito: a importância do setor público, das universidades e dos laboratórios públicos na investigação e no desenvolvimento de vacinas e de novos fármacos, a necessidade de disputar a hegemonia das multinacionais farmacêuticas, assegurar o primado do interesse público sobre o negócio. </p>
<p class="contents">A Covid veio tornar particularmente visível a perversidade do protagonismo concedido às multinacionais na aquisição de vacinas ainda em desenvolvimento. Com recursos públicos, financia-se a investigação, paga-se a compra de vacinas e, no fim, ainda se procura aliviar as empresas de obrigações relacionadas com condições de disponibilização de produtos e aliviá-las de riscos decorrentes da sua utilização. </p>
<p class="contents">O segundo requisito: a necessária consideração de estratégias nacionais que assegurem a cada país soberania neste domínio, o necessário reconhecimento a cada país do direito a produzirem, da necessidade de produzirem, obviamente, num quadro de necessária cooperação internacional neste domínio. Isto é particularmente importante no caso de países como Portugal, que estão muito dependentes neste domínio. O direito a produzir e à indústria farmacêutica não pode ser um exclusivo apenas de alguns países.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-043-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/38420.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:47:51&amp;playerEndTime=20201126-09:49:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Cristian-Silviu Buşoi (PPE).</span></span>   – Mr President, the sustainability of the healthcare sector is more and more challenging. Moreover, the COVID-19 pandemic has revealed many inefficiencies in our health system and deepened the existing challenges such as shortages.</p>
<p class="contents">I welcome the proposed EU pharma-strategy. There is a clear and strong signal from the Commission to ensure equitable access to medicines in the EU, both for innovative and generics. Access is uneven in several Member States and sometimes within regions. I also welcome the clear reference to remove excess barriers to generic and biosimilar medicines that is a key milestone also for countries like Romania, but not only.</p>
<p class="contents">A strong strategy is needed for pharmaceuticals, first to address shortages at the level of manufacturing and supply chains, one that will boost the production as well. And secondly to address the lack of innovation and fuel innovation.</p>
<p class="contents">With regard to rare diseases and cancers, I would like to echo some of my colleagues’ interventions: there are still too many diseases that have no cure and here, Commissioner, we should ensure that the reopening of the orphan legislation will still support a robust incentives framework for research and innovation.</p>
<p class="contents">As regards digitalisation, while I welcome the upcoming proposal on the health data space, I’m wondering if the Commission is thinking about introducing digitalisation also at the level of regulatory medicines authorities. Thank you so much and congratulations.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-044-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197721.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:49:29&amp;playerEndTime=20201126-09:50:29" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">César Luena (S&amp;D).</span></span>   – Señor presidente, señorías, esta crisis de la COVID-19 ha puesto de manifiesto los principales problemas que tenemos. Son problemas de precios, de deslocalización y de escasez de medicamentos y de productos sanitarios.</p>
<p class="contents">Lo primero que le pido, señora comisaria, es que cree una estructura. En la Estrategia usted habla de diálogo, pero yo creo que hace falta una <span class="italic">task force</span>, una estructura, para que pueda haber ese trabajo entre asociaciones de pacientes, entre administraciones y, también, entre la industria farmacéutica. Y le pido que apueste por la innovación genuina, no la incremental, que es la que hemos venido haciendo hasta ahora y no soluciona nuestros problemas.</p>
<p class="contents">Necesitamos también evaluar el valor terapéutico añadido de los nuevos medicamentos innovadores y ser referentes en materia de I+D. Le recuerdo que llevamos más de treinta años sin nuevos antibióticos, señora comisaria. Y, por último, señalar que el acceso a las terapias avanzadas no puede ser discriminatorio. Aprovechemos esta crisis para hacer una buena Estrategia.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-045-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197517.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:50:33&amp;playerEndTime=20201126-09:52:18" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Adam Jarubas (PPE).</span></span>   – Panie Przewodniczący! Pani Komisarz! Z uznaniem przyjmujemy założenia strategii farmaceutycznej. Kryzys COVID-19 pokazał dobitnie, że potrzebujemy wspólnotowych mechanizmów dla zaopatrzenia Europy w skuteczne, bezpieczne i przystępne cenowo leki, by wspomnieć zabezpieczaną przez Unię szczepionkę na COVID. Strategia farmaceutyczna wpisuje się w europejską unię dla zdrowia i skorzysta z europejskiego programu dla zdrowia EU4Health. Parlament Europejski potroił środki zaproponowane przez państwa w tym programie. Te ponad pięć miliardów euro to dwanaście razy więcej niż obecne finansowanie, to był priorytet europejskich ludowców. Pandemia to nie czas, by krajowe, partyjne rozgrywki rządowe <span class="italic">[zakłócenie dźwięku]</span> budżet Unii, środki które dosłownie mogą ratować życie. Potrzebujemy zatem zmian regulacyjnych i wsparcia Unii, przełamujących bariery ekonomiczne, przyspieszających wprowadzenie nowych antybiotyków, leków na choroby rzadkie czy onkologicznych. </p>
<p class="contents">W moim regionie w Polsce liczy na to na przykład Świętokrzyskie Centrum Onkologii wdrażające bardzo drogą spersonalizowaną terapię, której koszt można obniżyć sześciokrotnie, bo dzisiaj kosztuje to około 400 tys. euro. Unia musi odzyskać suwerenność lekową. Potrzebujemy strategicznego podejścia do bezpieczeństwa lekowego, uwzględnianego także przez krajowe programy refundacji. Jean Monet podkreślał, że Unia rozwija się nie pomimo kryzysów, a dzięki kryzysom. Dziś 66% obywateli Unii popiera zwiększenie kompetencji Unii w obszarze zdrowia. Wykorzystajmy to, aby zabezpieczyć europejski standard leczenia dla wszystkich obywateli.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-046-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112747.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:52:25&amp;playerEndTime=20201126-09:53:39" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Romana Jerković (S&amp;D).</span></span>   – Poštovani predsjedavajući, čestitam Komisiji na objavi nove Europske farmaceutske strategije. Pandemija je ukazala na brojne probleme i otvorila mnoga pitanja. Jedno od njih je i rastuća nejednakost među državama članicama u području kvalitetne zdravstvene skrbi.</p>
<p class="contents">Nova Farmaceutska strategija je dobar temelj za korjenite promjene koje nam predstoje, ali postoje aspekti koje nije dovoljno dobro prepoznala. Na primjer: do 2050. godine svjetska populacija porast će na 9 milijardi. Bit će teško osigurati adekvatnu zdravstvenu zaštitu ukoliko zdravstvene profesije i njihove srodne discipline i institucije ne budu radile zajedno, a preventivna medicina bit će iznimno važna. Mislim da strategija mora imati u tom aspektu puno važniju ulogu, i da se treba aktivnije uključiti u razvoj i promoviranje zdravih životnih navika, a ne biti fokusirana isključivo na liječenje bolesti.</p>
<p class="contents">Drugi aspekt tiče se utjecaja klimatskih promjena na kvalitetu života i zdravlja. Gubitkom biološke raznolikosti, zagađanjem zraka i zagrijavanjem planeta, raste broj novih zaraznih bolesti. Ignoriranje veze između klimatskih promjena i pandemija bila bi opasna zabluda.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-047-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197515.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:53:42&amp;playerEndTime=20201126-09:55:26" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Pernille Weiss (PPE).</span></span>   – Hr. Formand! Som borgerlig politiker er der ikke noget, jeg hellere vil, end at sikre, at ethvert menneske kan leve det liv, de gerne vil. Jeg skal ikke blande mig i, om den bløde krop har lidt ekstra deller, hvis kroppen i øvrigt har en glad sjæl. Men når vi i dag giver den nye pharmastrategi ord med på vejen, og mange af mine kollegaer meget klogt vælger at tale om covid, kritisk forsyningssikkerhed og det afgørende vigtige i at gøre EU til det bedste sted i verden at drive og udvikle lægemiddelindustrien, så vælger jeg at trække vores opmærksomhed hen på den skræmmende kendsgerning, at vi europæere ikke kun bliver ældre og ældre, færre og færre, vi bliver også federe og federe! Over halvdelen af os over 18 år er overvægtige eller stærkt på vej til at blive det. Det er mange, og som sygeplejerske bliver jeg også nødt til at sige, at det er for mange. Det er ikke bare almindelige hyggedeller, der glatter rynkerne ud og signalerer livsnydelse. Der er tale om fedme i en grad, der indebærer ekstrem høj risiko for at udvikle insulinkrævende diabetes, meget høj risiko for kræft eller en af de andre 230 diagnoser, der rammer mennesker med overvægt. 2,8 millioner europæere dør årligt af overvægt. Og jeg er ked af at sige det, det koster også statskassen, det går altså ikke. Som borgerlig vil det være socialt og etisk uansvarligt, hvis vi ikke husker, at når vi nu skal ud og rulle pharmastrategien ud, så skal vi huske overvægten også, den skal højt op på dagsordenen. Lige fra digitale løsninger ind i vores fælles politikker osv. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-048-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197523.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:55:32&amp;playerEndTime=20201126-09:56:36" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Łukasz Kohut (S&amp;D).</span></span>   – Mr President, First of all I would like to say that I am not a big fan of widespread government regulation of the economy. In my opinion, markets are far more productive if they are competitive. However, when it comes to critical infrastructure markets, one has to admit that they cannot be left unsupervised. The European market for pharmaceutical products is one such market. The pandemic has proven that it needs more regulation and coordination so that patients receive the best possible access to medicines and medical treatments.</p>
<p class="contents">For this reason, I welcome the new pharmaceutical strategy, which the Commission adopted yesterday. I especially welcome proposals for actions aimed at increasing the accessibility of medicines for the treatment of childhood cancer or rare diseases. This has not been a priority for producers so far. </p>
<p class="contents">I’m looking forward, and committed, to working with the Commission and other actors on the implementation of the strategy in order to achieve higher standards of healthcare and to protect citizens’ well—being.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-049-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/193419.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:56:40&amp;playerEndTime=20201126-09:58:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Christophe Hansen (PPE).</span></span>   – Herr Präsident, Frau Kommissarin! Wie Sie sehen, gibt es eine sehr breite Unterstützung für Ihre Pharmastrategie in diesem Haus, und das ist auch gut so. Ich wünsche mir natürlich auch, dass die Mitgliedstaaten genauso optimistisch an die Sache rangehen werden, weil es auch die Mitgliedstaaten sind, die in der Vergangenheit zu wenig mitgespielt haben, wenn es um gemeinsame EU-Gesundheitspolitik geht. Das ist ganz klar. </p>
<p class="contents">Wir müssen aber jetzt auch schon feststellen: Es braucht Zeit, bis diese neue Strategie auch konkrete Rückfolgen auf unser Leben in der EU hat. Deshalb müssen wir auch sicherstellen, dass das, was schon in Kraft ist und in Kraft tritt, von den Mitgliedstaaten auch richtig umgesetzt wird.</p>
<p class="contents">Ich bin Berichterstatter für die Trinkwasserrichtlinie, die wir im nächsten Plenum – das Abkommen – hier durchwinken werden. Da haben wir auch festgestellt, dass hormonaktive Stoffe stärker unter die Lupe genommen werden müssen. Frau Ries hatte das schon angesprochen.</p>
<p class="contents">Wir müssen versuchen, mehr Wiederansiedlung von Produktion in der Europäischen Union zu haben. Das wird aber auch Zeit brauchen, deshalb brauchen wir eine Diversifizierung unserer Lieferketten. Ich könnte mir vorstellen, dass Sie da auch einen spezifischen Fonds einsetzen würden, um unseren Betrieben zu helfen, nicht von einem einzigen Zulieferer abhängig zu sein.</p>
<p class="contents">Wir haben auch festgestellt, dass wir in diesen Zeiten besonders mit Drittländern Probleme hatten, wo wir keine Handelsabkommen haben. Das heißt, wir müssen auch unsere Handelspolitik dementsprechend anpassen, mehr Handelsabkommen machen, weil uns das helfen wird, da unabhängiger zu werden.</p>
<p class="contents">Ich bin sehr froh, dass auch Kommissar Dombrovskis anwesend ist – wir haben die Überprüfung der Handelspolitik, die auf der Agenda steht. Auch da, Frau Kyriakides, müssen Sie mit eingreifen, damit wir konkrete Resultate haben.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-050-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197492.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-09:58:30&amp;playerEndTime=20201126-10:00:08" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bartosz Arłukowicz (PPE).</span></span>   – Panie Przewodniczący! Pani Komisarz! Europa i świat toczą walkę z COVID-19 i ta walka nauczyła nas wszystkich, że tak naprawdę w pojedynkę nie mamy żadnych szans z globalnymi wyzwaniami takimi jak COVID ani z innymi wyzwaniami i nową walką, u progu której stoimy. To jest walka o pacjentów z rakiem. Niestety w najbliższych miesiącach do europejskich szpitali trafią miliony pacjentów ze zbyt późno rozpoznaną chorobą nowotworową, często w zaawansowanym stopniu, pewnie z przerzutami, a czasem w stanie terminalnym, bo COVID opóźnia leczenie, opóźnia diagnozy, opóźnia pomoc. W związku z tym już dzisiaj musimy podjąć, Pani Komisarz, strategiczną decyzję o zbudowaniu systemu ciągłości dostaw leków nowotworowych. My dzisiaj musimy zbudować strategiczny zapas leków nowotworowych, krytycznych leków nowotworowych, dzięki którym pomożemy pacjentom. </p>
<p class="contents">Wyzwanie drugie, które stoi dzisiaj przed nami po doświadczeniach COVIDowych, to zbudowanie sprawnego systemu reagowania na sytuacje krytyczne i nagłe. Musi zostać zbudowany system maksymalnie szybkiego przekazywania informacji między rządami i wspólnego reagowania w postaci kupowania leków czy zabezpieczania sprzętu. Te dwa wyzwania – strategiczne zapasy leków w Europie i system reagowania na sytuacje kryzysowe, to największe wyzwania, przed jakimi stoimy dzisiaj my, stoi Pani Komisarz i cała Europa. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-051-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197427.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-10:00:12&amp;playerEndTime=20201126-10:01:42" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mortler (PPE).</span></span>   – Herr Präsident! Zu Pernille Weiss: Solange man mit Fettverbrenner-Tabletten mehr Geld verdient als mit neuen Antibiotika, stimmt etwas nicht im System. Danke.</p>
<p class="contents">Ich begrüße die europäische Pharmastrategie außerordentlich, denn die Corona-Krise hat gezeigt, dass wir nur gemeinschaftlich weiterkommen. Unsere Landwirtschaft ist zum Beispiel als Sektor für unsere Ernährungssicherheit von strategischer Bedeutung. COVID-19 hat uns ebenfalls vor Augen geführt, dass wir eine robuste Gesundheits- und Medikamentenversorgung sowie resiliente, diversifizierte Lieferketten für unsere Bürgerinnen und Bürger sicherstellen müssen.</p>
<p class="contents">Wir brauchen also einerseits eine wettbewerbsfähige Pharmaindustrie mit attraktiven und verlässlichen Rahmenbedingungen für Forschung, Entwicklung, Regulierung und Zulassung, und um den Weg zu neuen und innovativen Therapien und Medikamenten zu erleichtern und zu beschleunigen. Ich denke an öffentliche, öffentlich-private Forschungskooperationen mit struktureller und finanzieller Förderung.</p>
<p class="contents">Andererseits müssen alle Patienten – ohne Ausnahme – eine notwendige Behandlung zu einem erschwinglichen Preis erhalten. Dass die Mitgliedstaaten bei der gemeinsamen Beschaffung von Impfstoffen schon gut vorangekommen sind, ist hoffnungsvoll, denn auf die nächste Pandemie müssen wir besser und schneller vorbereitet sein.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-052-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197417.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-10:01:49&amp;playerEndTime=20201126-10:03:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tomislav Sokol (PPE).</span></span>   – Poštovani predsjedavajući, Farmaceutska strategija za Europu temelji se na holističkom pristupu usmjerenom na pacijente, kojom će se osigurati opskrba sigurnim i cjenovno pristupačnim lijekovima kako bi se zadovoljile potrebe svih pacijenata i zajamčila održivost zdravstvenih sustava. </p>
<p class="contents">Nestašica lijekova dugogodišnji je problem. Istraživanje iz 2019., koje je obuhvatilo 24 države članice, pokazalo je da svaka četvrta država nema sustav prijave nestašice lijekova i da su njihove ljekarne imale problema s nestašicom lijekova. Glavni izazov je što se gotovo 80 % aktivnih sastojaka za proizvodnju lijekova uvozi iz trećih država. Glede toga, smatram da se u Europskoj uniji trebaju stvoriti uvjeti i reducirati birokracija i regulatorne prepreke kako bi se farmaceutska industrija dovela što više i omogućio njen razvoj u svim dijelovima Europske unije, uključujući i one slabije razvijene. Da bismo to uspjeli, europska ulaganja putem niza instrumenata, kao što su Obzor, EU za zdravlje, InvestEU, Digitalna Europa i posebno kohezijska politika, moraju djelovati sinergijski. Jedan od konkretnih modela buduće europske suradnje tiče se pristupa inovativnim lijekovima. Oni nisu dostupni prvenstveno danas jer su skupi. Postoji model koji bi omogućio veću dostupnost skupih lijekova, a to je zajednička europska javna nabava. Matematika je jednostavna - ako Europska unije pregovara kao cjelina, pregovaračka pozicija država članica je znatno povoljnija, a konačna cijena lijekova za zdravstvene sustave i građane jeftinija. </p>
<p class="contents">Vrijeme je da zajedničkom nabavom omogućimo niže cijene skupih lijekova, primarno za rijetke bolesti i dječje karcinome.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-053-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197648.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-10:03:36&amp;playerEndTime=20201126-10:05:20" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alexander Bernhuber (PPE).</span></span>   – Herr Präsident, sehr geehrte Frau Kommissarin! Die Arzneimittelstrategie ist vielversprechend, aber auch längst überfällig, und der Hut brennt wirklich. Wir haben in Europa seit Jahren schon immer wieder mit Medikamentenengpässen zu kämpfen, und hier muss die Kommission wirkliche Fortschritte zeigen.</p>
<p class="contents">Die Zahl an knappen Medikamenten hat sich von 2000 bis 2018 mehr als verzwanzigfacht. Mehr als die Hälfte der benötigten Arzneimittel ist nicht lieferbar, und auf lebenswichtige Krebsmedikamente und Schmerzmittel müssen Patienten lange warten. </p>
<p class="contents">Die Pandemie hat diese erschreckenden Missstände noch mehr aufgezeigt. Es gab Engpässe an Schutzausrüstungen, Medikamente wurden einfach nicht geliefert; hier gibt es großen Handlungsbedarf.</p>
<p class="contents">Das Problem dahinter ist, dass ein Großteil der Arzneimittel aus dem Ausland kommt. Über 80 % der pharmazeutischen Wirkstoffe kommen aus Asien, und 40 % der in der EU verkauften Medikamente werden in China oder Indien produziert. Das bedeutet für Patienten oft lange Wartezeiten, unnötige Mehrbelastungen. </p>
<p class="contents">Hier ist es ganz wichtig und mein großer Appell, die Produktion wieder zurück nach Europa zu holen. Es werden Milliarden in die Beschaffung von Medikamenten investiert, und hier muss auch zukünftig die Beschaffung von europäischen Medikamenten mehr berücksichtigt werden. Frau Kommissarin, ich bitte Sie, gleich vorbildhaft bei der Beschaffung von COVID-Impfstoff zu sein, hier auf europäische Produktion zu achten. </p>
<p class="contents">Die europäische Arzneimittelversorgung ist wichtig und muss ein großes gemeinschaftliches Ziel sein. Hier ist es besonders wichtig, und ich bitte Sie, dies in der Arzneimittelstrategie zu berücksichtigen.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-054-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-10:05:29&amp;playerEndTime=20201126-10:17:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stella Kyriakides,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Mr President, I would like to thank honourable Members very much for the very inspiring discussion. You have raised a large number of points. I’ll try to cover as much as possible and I’m sure we’ll have many opportunities to discuss this further.</p>
<p class="contents">First of all, there were questions on the need to revise the rules for rare diseases and children. I want to say that we have already evaluated the legislation on medicines for rare diseases and children. This evaluation has shown that there are already a number of shortcomings. The main problems identified here are insufficient development and in the areas of the greatest unmet medical needs, as I have mentioned. So we will be holding more consultations with stakeholders in the next year and we will be moving forward in order to be able to have a fair and balanced system where we refer to rare diseases and children. </p>
<p class="contents">Again, in the same area, there were some questions on how we can push pharmaceutical companies to invest in rare diseases and unmet needs. For example, paediatric cancers appear to be of limited interest for the industry. We need to look at this. Our first step will be to review the legislation on medicines for children and rare diseases. Our objective is simple: to improve the therapeutic landscape and address unmet needs through more tailored incentives. We will foresee the adoption of a new proposal by 2022. </p>
<p class="contents">On AMR: there were several questions on antimicrobial resistance. It is a major threat. COVID—19 has further highlighted this. Currently, we see that there’s a weak and challenging business case to invest in the development of new antimicrobials. One of the reasons is that its use must remain restricted once placed on the market. We will be aiming to tackle this in two ways: to measure the reduce and use and ensure the appropriate use of antimicrobials, and also incentivise the development of new classes of antimicrobials. This will be done through both legislative and non-legislative proposals. </p>
<p class="contents">Another point that was raised by several of you is access to medicines, a huge issue. This is a key priority. I have said it from the beginning. There can be no first and second-class citizens in the EU. Everyone should have the right of access to the same treatments and the inequalities we see at the moment are simply unacceptable. We need to change this so we will be proposing concrete actions. We will be linking incentives for innovation with obligations for the companies, we will be initiating with the European Medicines Agency (EMA) and Member States a pilot to engage in this, and we will be improving access for generics and biosimilars, which many of you have mentioned.</p>
<p class="contents">Regarding environmental challenges, the strategy will be addressing the whole lifecycle of pharmaceuticals and we will be proposing to reform our pharma legislation to ensure environmental sustainability, but not only, by also strengthening cooperation with our international partners to ensure quality and environmental sustainability of active pharmaceutical ingredients (APIs) currently imported from non-European countries. </p>
<p class="contents">I mentioned generic and biosimilars. This is a very important question because it really can provide patients with access to affordable treatments. We will look to reform the pharma legislation to better promote competition of such products. Regarding affordability, availability of medicines goes hand in hand with affordability so we’ll be promoting and supporting cooperation between national authorities to exchange best practice and will also be looking at improving transparency on the methods for establishing the research and development of medicines.</p>
<p class="contents">On the issue of data, next year we will be presenting the European health data space. This will aim to facilitate access and the exchange of health data. This would really change the way that health systems and patient access are being seen at the moment. But we do need to understand that health data is also very sensitive so we need to ensure a high level of protection. We will be engaging closely with citizens to make sure that they can understand this.</p>
<p class="contents">In terms of the production of medicinal products and because I have mentioned strategic autonomy and there were some questions on this, I want to be absolutely clear that the EU will remain open and promote open trade. Protectionism is not in the DNA of the European Union, but strategic economy is a political objective of this strategy and it’s also a major lesson learned from COVID—19. But, first of all, we need to have a better understanding of the supply chain design and identify its vulnerability in order to be able to move forward, while continuing to diversify our supply sources, wherever necessary manufacturing in Europe, and working more closely with our third—country trading partners.</p>
<p class="contents">Trade came up again when we were discussing the security of supply. We are exploring, in the context of the World Trade Organization, the launching of an initiative facilitating trade in health products in emergency situations and also looking at how we can explore with the EU’s trading partners to conclude a multilateral agreement on tariff elimination on pharmaceutical and medical goods.</p>
<p class="contents">Regarding intellectual property and the pharmaceutical strategy, I will try to be very brief. Any revisions to the rules of intellectual property and pharmaceutical investment incentives will address the need to foster innovation and make medicines available to all patients at an affordable price. So innovation needs to match the needs and match the needs of patients. </p>
<p class="contents">We have already addressed shortages, but what we need to understand is that what we all need to work on together is to ensure that medicines are available to patients in need and at all times, whether it is a time of crisis or not. The patient is really at the heart of this initiative. Because the causes of medicine shortages are complex, before moving forward we have launched a study on the root causes of medicine shortages. This will be finalised in the second half of 2021 and we will then be able to promote specific actions. </p>
<p class="contents">Regarding what we done in the last few months – because there were several questions on that – to address it, I won’t list all the actions, but I can say that, from the very beginning of this pandemic, I personally, and with Commissioner Breton, have engaged with industry, asking them to increase production capacity where we identified increased demand. We adopted guidelines to promote optimal supply of medicines and we launched joint procurement to address shortages of critical hospital medicines. So a great deal has been done, but we need to put this into place so that, at a time of crisis, we already have everything in place that we need to have.</p>
<p class="contents">Regarding innovation, this is really one of the things at the heart of the pharmaceutical legislation proposals and we need to make the necessary adaptations in order for our legislation to be really more innovation friendly. This will also deal with bottlenecks and improve regulatory gaps that we may have. We need to give incentives to industry, but we also expect accessibility to medicines to be improved and inequalities of access to disappear from the EU.</p>
<p class="contents">There were one or two questions on cancer. The Europe Beating Cancer Plan is shortly going to be presented before you, but we know that cancer is a major cause of death in children after infancy and so we are looking at the revision of the Orphan and Paediatric Regulation to ensure this. We need to do more in the treatment of paediatric cancers and this pharmaceutical strategy will interact very closely with the Europe Beating Cancer Plan because it will support the goal of sustainable cancer prevention with the right incentives for innovation, for a vaccination against treatable infections that cause cancer and much more.</p>
<p class="contents">And, yes, we propose to amend the role of the European Medicines Agency (EMA). I have already analysed this when presenting the European health union. I have absolutely no doubt that this is the way forward for a stronger European health union. We will need to strengthen our agencies in order for them to deliver what we expect them to deliver.</p>
<p class="contents">I’d like to end by answering what several honourable Members mentioned on the issue of competencies. We are very well aware of the competencies, as of course is the European Parliament and the Council, but we’re also very well aware of the importance of solidarity and coordination. Everything we have put forward, in terms of the European health union and in terms of the pharmaceutical strategy, takes into account and is well within the Treaty. But we have also learned from COVID—19 that we need to be flexible and we need to try and work, using the Treaty, to all the limits that it can give us and all the boundaries so that we can move forward.</p>
<p class="contents">I very much look forward to your support for this strategy. We need to have the support of the European Parliament. I want to thank you on a personal basis, because I’ve had the opportunity to speak with many of you over the last few months, for the support for EU for health and the increase in the budget. This is a very important part for us. </p>
<p class="contents">What I can end by saying is that, with President von der Leyen and with all my colleagues, all the Commissioners, we are going to leave no stone unturned until we find the way out of this pandemic. We need to seize the opportunity of this crisis to come out stronger, stronger in the area of health, and deliver to citizens what they expect – a stronger European health union. This is what they have asked us for from the beginning of this crisis and this is what we should all be working together to deliver. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-055-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4246.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20201126-10:17:26&amp;playerEndTime=20201126-10:17:40" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Der Präsident. – </span></span>  Die Aussprache ist geschlossen.</p>
<p class="contents"><span class="bold"><span class="italic">Schriftliche Erklärungen (Artikel 171)</span></span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-055-1250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/197718.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicolás González Casares (S&amp;D), </span></span>  <span class="italic">por escrito</span><span class="bold">.</span> – La adopción de la Estrategia Farmacéutica para Europa es sin duda un paso adelante en la construcción de una Unión Europea de la Salud. </p>
<p class="contents">El Grupo S&amp;D viene demandando desde hace tiempo una mayor acción para garantizar el acceso a medicamentos seguros, eficaces y asequibles, y celebra ver que la propuesta presentada por la Comisión sugiere acciones concretas para alcanzar dichos objetivos. </p>
<p class="contents">Los socialistas españoles esperamos que la Comisión cree una estructura en la que pueda haber un trabajo conjunto de asociaciones de pacientes, administraciones e industria farmacéutica. Además, reclamamos una mayor inversión en investigación genuina, no incremental, que evalúe el valor terapéutico añadido de los nuevos medicamentos innovadores y que convierta a la UE en un referente terapéutico en I+D. </p>
<p class="contents">La pandemia de la COVID-19 debe servirnos de lección para crear una buena estrategia farmacéutica. Las futuras medidas deben centrarse en los pacientes, garantizando un acceso igualitario a medicamentos y terapias para todos los ciudadanos europeos. El fin último es asegurar la salud de todos y construir una Europa más resiliente ante futuras crisis sanitarias.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-055-2500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125042.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Javi López (S&amp;D), </span></span>  <span class="italic">por escrito</span><span class="bold">.</span> – La adopción de la Estrategia Farmacéutica para Europa es sin duda un paso adelante en la construcción de una Unión Europea de la Salud. </p>
<p class="contents">El Grupo S&amp;D viene demandando desde hace tiempo una mayor acción para garantizar el acceso a medicamentos seguros, eficaces y asequibles, y celebra ver que la propuesta presentada por la Comisión sugiere acciones concretas para alcanzar dichos objetivos. </p>
<p class="contents">Los socialistas españoles esperamos que la Comisión cree una estructura en la que pueda haber un trabajo conjunto de asociaciones de pacientes, administraciones e industria farmacéutica. Además, reclamamos una mayor inversión en investigación genuina, no incremental, que evalúe el valor terapéutico añadido de los nuevos medicamentos innovadores y que convierta a la UE en un referente terapéutico en I+D. </p>
<p class="contents">La pandemia de la COVID-19 debe servirnos de lección para crear una buena estrategia farmacéutica. Las futuras medidas deben centrarse en los pacientes, garantizando un acceso igualitario a medicamentos y terapias para todos los ciudadanos europeos. El fin último es asegurar la salud de todos y construir una Europa más resiliente ante futuras crisis sanitarias.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-055-3750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/33982.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marian-Jean Marinescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">.</span> – Avem obligația să le garantăm cetățenilor accesul egal la medicamente. Medicamentele trebuie să aibă un preț accesibil tuturor, să nu lipsească din farmacii, să nu trebuiască să înlocuim medicamentele noi și mai eficiente cu cele vechi, din cauza prețurilor prohibitive sau să aflăm că pentru bolile rare nu există medicamente doar pentru că, prin natura lor, nu sunt profitabile pentru companiile farmaceutice. </p>
<p class="contents">Comisia Europeană ne-a prezentat în această sesiune plenară, noua strategie farmaceutică. Un demers pe care îl consider binevenit pentru a da aplicabilitate celorlalte programe din sănătate, precum „UE pentru sănătate” sau viitorul Plan european pentru combaterea cancerului. Ambele sunt programe ambițioase, cu obiective salutare. Însă, dacă nu reușim să le asigurăm oamenilor un drept esențial cum este accesul la medicamentele de care au nevoie, atunci toate aceste obiective vor rămâne pe hârtie. </p>
<p class="contents">Noua strategie farmaceutică trebuie să garanteze: accesul egal la medicamente, preț accesibil al medicamentelor inovative, disponibilitatea acestora în toate statele membre, medicamente accesibile pentru bolile rare, transparența costurilor de dezvoltare a unui nou medicament, independența farmaceutică a UE prin relocarea producerii substanțelor de bază, chiar dacă costurile companiilor farmaceutice cu forța de muncă vor crește.</p>
<p class="contents">În abordarea noii strategii farmaceutice trebuie să încetăm să mai privim medicamentele ca bunuri comerciale și să le considerăm bunuri existențiale.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-055-5000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/27714.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Edina Tóth (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">.</span> – Az egész világon tomboló koronavírus és az egyre öregedő európai társadalom rámutatott arra, hogy a tagállamoknak egyre növekvő egészségügyi kockázattal kell szembenézniük, amely a társadalom számára is sokkal nagyobb terhet jelent. Nem elhanyagolható az a tény sem, hogy napjainkban egyre inkább megfigyelhető a gyógyszerellátási lánc egyre merevebbé válása, az európai gyógyszeripar részesedése egyre hanyatlik és az európai egészségügy rendkívüli mértékben függ a harmadik országbeli termeléstől és az onnan történő behozataltól. Ezáltal egyes területeken sebezhetővé válik, ami súlyos esetekben akár gyógyszerhiányhoz is vezethet. Ugyanakkor fontos kiemelni, hogy a gyógyszeripar nem hasonlítható a többi iparághoz és a gyógyszereket sem lehet más árucikkhez hasonlítani. Az ellátási zavarok sokkal jobban hatnak az emberek életére és életminőségére, mint más termékek. Éppen ezért tartom rendkívül fontosnak az európai gyógyszeripari stratégiát, amely a megfelelő kivitelezés esetén egyedülálló lehetőséget biztosíthat az Európai Unió számára, hogy megerősítse Európa szerepét a globális gyógyszergyártásában. Bár a stratégiával kapcsolatban még sok a kérdés és hiányzó információ, jó okunk van arra, hogy támogassuk a startégiában foglalt célkitűzések megvalósítását és az európai gyógyszergyártás megerősítését célzó törekvéseket.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td>Last updated: 11 February 2021</td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
